Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation (OPTION): A Randomized, Open-Label, End Point–Blinded, Noninferiority Trial
Circulation · 17.01.2023 · 147 (3) · 212-222
DOI: 10.1161/circulationaha.122.062762 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Circulation, erschienen am 17.01.2023. Verfasst von Hongyi Wu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for …. Hauptthemen laut MEDLINE: Drug-Eluting Stents, Myocardial Infarction. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Shanghai Clinical Research Center, Zhongshan Hospital, Hangzhou Zhongmei Huadong Pharmaceutical Company.
Abstract (Originalsprache)
Background
Dual antiplatelet therapy (DAPT) with aspirin as a background therapy has become the standard care after percutaneous coronary intervention. However, some adverse noncardiac effects limited the use of aspirin in clinical practice. Thus, evaluation of pharmacological alternatives to aspirin is attractive. Previous data indicated that indobufen could lessen the unwanted side effects of aspirin while retaining the antithrombotic efficacy, but its combination with a P2Y 12 inhibitor still lacks randomized clinical trial evidence.
Methods
In this randomized, open-label, noninferiority trial, patients with negative cardiac troponin undergoing coronary drug-eluting stent implantation were randomly assigned in a 1:1 ratio to receive either indobufen-based DAPT (indobufen 100 mg twice a day plus clopidogrel 75 mg/d for 12 months) or conventional DAPT (aspirin 100 mg/d plus clopidogrel 75 mg/d for 12 months). The primary end point was a 1-year composite of cardiovascular death, nonfatal myocardial infarction, ischemic stroke, definite or probable stent thrombosis, or Bleeding Academic Research Consortium criteria type 2, 3, or 5 bleeding. The end points were adjudicated by an independent Clinical Event Committee.
Results
Between January 11, 2018, and October 12, 2020, 4551 patients were randomized in 103 cardiovascular centers: 2258 patients to the indobufen-based DAPT group and 2293 to the conventional DAPT group. The primary end point occurred in 101 patients (4.47%) in the indobufen-based DAPT group and 140 patients (6.11%) in the conventional DAPT group (absolute difference, −1.63%; P noninferiority 0.05). The occurrence of Bleeding Academic Research Consortium criteria type 2, 3, or 5 bleeding events was lower in the indobufen-based DAPT group compared with the conventional DAPT group (2.97% versus 4.71%; hazard ratio, 0.63 [95% CI, 0.46–0.85]; P =0.002), with the main decrease in type 2 bleeding (1.68% versus 3.49%; hazard ratio, 0.48 [95% CI, 0.33–0.70]; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, China (H.Y.W., L.L.X., X.Z., C.Z., Y.M.W., J.…
- Department of Cardiology, Taian City Central Hospital, Shandong, China (H.Y.Z.).
- Department of Cardiology, Xi'an No. 3 Hospital, Affiliated Hospital of Northwest University, Xi'an, Shanxi, China (K.C.).
- Department of Cardiology, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China (X.Y.W.).
- Department of Cardiology, Central Hospital of Wuhan, Hubei, China (M.H.C.).
- Department of Cardiology, Second Hospital of Tianjin Medical University, China (G.P.L.).
ORCID-Profile: Juying Qian, Junbo Ge
Förderung
- Shanghai Clinical Research Center
- Zhongshan Hospital
- Hangzhou Zhongmei Huadong Pharmaceutical Company
Zitieren
APA
Wu, H., Xu, L., Zhao, X., Zhang, H., Cheng, K., Wang, X., Chen, M., Li, G., Huang, J., Lan, J., Wei, G., Zhang, C., Wang, Y., Qian, J., Ge, J., & OPTION Investigators (2023). Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation (OPTION): A Randomized, Open-Label, End Point–Blinded, Noninferiority Trial. Circulation, 147(3), 212-222. https://doi.org/10.1161/circulationaha.122.062762
Vancouver
Wu H, Xu L, Zhao X, Zhang H, Cheng K, Wang X, et al. Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation (OPTION): A Randomized, Open-Label, End Point–Blinded, Noninferiority Trial. Circulation. 2023;147(3):212-222. doi:10.1161/circulationaha.122.062762
BibTeX
@article{Wu2023,
author = {Wu, Hongyi and Xu, Lili and Zhao, Xin and Zhang, Huanyi and Cheng, Kang and Wang, Xiaoyan and Chen, Manhua and Li, Guangping and Huang, Jiangnan and Lan, Jun and Wei, Guanghe and Zhang, Chi and Wang, Yinman and Qian, Juying and Ge, Junbo and OPTION Investigators, OPTION Investigators},
title = {Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation (OPTION): A Randomized, Open-Label, End Point–Blinded, Noninferiority Trial},
journal = {Circulation},
year = {2023},
volume = {147},
number = {3},
pages = {212--222},
doi = {10.1161/circulationaha.122.062762}
}
EUVIMED